Knight Therapeutics Inc. provided revenue guidance for the fiscal year 2024. For the period, the company expected to generate revenues between $335 million to $350 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 CAD | +1.46% | +2.77% | +7.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.13% | 405M | |
+7.95% | 72.21B | |
+14.98% | 9.14B | |
-24.60% | 4.33B | |
+15.26% | 4.28B | |
+28.46% | 4.15B | |
+7.76% | 2.19B | |
-35.98% | 1.98B | |
+7.76% | 1.98B | |
-47.71% | 1.68B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024